iRhythm Technologies, Inc. (IRTC): Price and Financial Metrics
GET POWR RATINGS... FREE!
IRTC POWR Grades
- Growth is the dimension where IRTC ranks best; there it ranks ahead of 64.03% of US stocks.
- IRTC's strongest trending metric is Growth; it's been moving up over the last 179 days.
- IRTC ranks lowest in Value; there it ranks in the 8th percentile.
IRTC Stock Summary
- With a market capitalization of $4,504,285,016, IRHYTHM TECHNOLOGIES INC has a greater market value than 74.43% of US stocks.
- With a price/sales ratio of 12.45, IRHYTHM TECHNOLOGIES INC has a higher such ratio than 90.61% of stocks in our set.
- Over the past twelve months, IRTC has reported earnings growth of 120.62%, putting it ahead of 87.38% of US stocks in our set.
- Stocks that are quantitatively similar to IRTC, based on their financial statements, market capitalization, and price volatility, are NVRO, ADN, LUNG, FTCI, and XXII.
- Visit IRTC's SEC page to see the company's official filings. To visit the company's web site, go to www.iRhythmTech.com.
IRTC Valuation Summary
- In comparison to the median Healthcare stock, IRTC's price/earnings ratio is 243.88% lower, now standing at -28.2.
- IRTC's price/sales ratio has moved down 0.6 over the prior 72 months.
Below are key valuation metrics over time for IRTC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| IRTC | 2022-09-23 | 10.2 | 15.1 | -28.2 | -29.1 |
| IRTC | 2022-09-22 | 10.7 | 15.9 | -29.7 | -30.7 |
| IRTC | 2022-09-21 | 11.0 | 16.3 | -30.4 | -31.4 |
| IRTC | 2022-09-20 | 12.9 | 19.1 | -35.7 | -36.9 |
| IRTC | 2022-09-19 | 12.7 | 18.8 | -35.2 | -36.3 |
| IRTC | 2022-09-16 | 12.5 | 18.4 | -34.5 | -35.6 |
IRTC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- IRTC has a Quality Grade of C, ranking ahead of 48.79% of graded US stocks.
- IRTC's asset turnover comes in at 0.621 -- ranking 69th of 186 Medical Equipment stocks.
- STRR, TCMD, and RSLS are the stocks whose asset turnover ratios are most correlated with IRTC.
The table below shows IRTC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.621 | 0.712 | -0.132 |
| 2021-03-31 | 0.626 | 0.719 | -0.149 |
| 2020-12-31 | 0.676 | 0.735 | -0.110 |
| 2020-09-30 | 0.721 | 0.741 | -0.140 |
| 2020-06-30 | 0.777 | 0.740 | -0.194 |
| 2020-03-31 | 0.834 | 0.755 | -0.165 |
IRTC Price Target
For more insight on analysts targets of IRTC, see our IRTC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $66.40 | Average Broker Recommendation | 1.83 (Hold) |
IRTC Stock Price Chart Interactive Chart >
IRTC Price/Volume Stats
| Current price | $121.67 | 52-week high | $169.54 |
| Prev. close | $122.73 | 52-week low | $56.49 |
| Day low | $120.27 | Volume | 266,347 |
| Day high | $125.46 | Avg. volume | 392,742 |
| 50-day MA | $149.43 | Dividend yield | N/A |
| 200-day MA | $133.20 | Market Cap | 3.65B |
iRhythm Technologies, Inc. (IRTC) Company Bio
iRhythm Technologies, Inc., a digital healthcare company, focuses on the provision of ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias in the United States. It offers ZIO Service, a platform that provides wearable biosensor with cloud-based data analytics that distill data from heartbeats into clinically actionable information. The company was founded in 2006 and is based in San Francisco, California.
Latest IRTC News From Around the Web
Below are the latest news stories about IRHYTHM TECHNOLOGIES INC that investors may wish to consider to help them evaluate IRTC as an investment opportunity.
iRhythm Technologies (NASDAQ:IRTC) Drops After Business UpdateiRhythm Technologies (NASDAQ:IRTC) shares are tanking in the trade today after an update on its guidance for 2022. The digital health care company is eyeing $1+ billion in revenues by 2027. It has reiterated its earlier guidance for 2022. Revenue is expected to land between $415 million and $420 million. Further, adjusted EBITDA is expected to range between negative $12.5 million and negative $17.5 million. |
iRhythm Technologies Details Growth Strategies at 2022 Analyst & Investor DaySAN FRANCISCO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent and predict disease, will discuss the Company’s strategies for long-term growth, provide an update on its innovation pipeline and share its financial goals during its 2022 Analyst & Investor Day today in New York City. A live webcast of the event will begin at 9:00 a.m. ET and will be accessible at that time |
iRhythm Technologies to Host Analyst & Investor Day on September 21, 2022SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the Company will host an Analyst & Investor Day on Wednesday, September 21, 2022, in New York City. A live webcast of the event will begin at 9:00 a.m. ET and will be accessible at that time on the investors section of the Company’s website at investors.irhythmtech.com. A replay of the webcast and r |
iRhythm Technologies, Inc. Common Stock (IRTC) Q2 2022 Earnings Call TranscriptEarlier today, iRhythm released financial results for the second quarter ended June 30, 2022. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. |
iRhythm Reports Smaller Than Expected Q2 Loss; Narrows Annual Sales GuidanceiRhythm Technologies Inc (NASDAQ: IRTC) posted a Q2 adjusted loss of $(0.79) compared to a loss of $(0.59) a year ago, beating the consensus of $(0.92) Sales reached $102.1 million, beating the consensus of $100.12 million. Revenue was up 25.6% year-over-year, primarily driven by volume growth of the Zio XT and AT single-use monitors and increases in Medicare pricing. The gross margin improved to 68.8%, up from 68.0% a year ago, primarily due to increased volume and average selling price, partia |
IRTC Price Returns
| 1-mo | -17.63% |
| 3-mo | 7.14% |
| 6-mo | -19.64% |
| 1-year | 108.30% |
| 3-year | 64.22% |
| 5-year | 135.48% |
| YTD | 3.38% |
| 2021 | -50.39% |
| 2020 | 248.38% |
| 2019 | -2.00% |
| 2018 | 23.96% |
| 2017 | 86.83% |
Continue Researching IRTC
Want to do more research on iRhythm Technologies Inc's stock and its price? Try the links below:iRhythm Technologies Inc (IRTC) Stock Price | Nasdaq
iRhythm Technologies Inc (IRTC) Stock Quote, History and News - Yahoo Finance
iRhythm Technologies Inc (IRTC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...